Evidence map›Paper›PMID 42027414›Full record

ArticleThe Journal of clinical and aesthetic dermatology2026

A Multicenter Trial Evaluating the Safety and Efficacy of a Serum Containing Plant Adaptogens in Patients With Mild-to-Moderate, Persistent Centrofacial Erythema Associated With Rosacea.

Zoe Diana Draelos, Jacqueline Watchmaker, Diane B Nelson

Abstract read
In one paragraph

Article in The Journal of clinical and aesthetic dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Zoe Diana DraelosDr. Draelos is with Dermatology Consulting Service, PLLC in High Point, North Carolina.
Jacqueline WatchmakerDr. Watchmaker is with Southwest Skin Specialists in Scottsdale, Arizona.
Diane B NelsonMs. Nelson is a former employee of Skinbetter Science, a Dermatological Beauty Brand of L'Oreal USA, Inc.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPersistent facial erythema is one of the most common subtypes of rosacea, often prompting patients to seek treatment. Characterized by multiple factors including adaptive immune and vascular dysregulation, genetics, and environmental influences, skincare measures aimed at reducing erythema and strengthening the skin barrier are fundamental to treatment. Plant adaptogens are rich phytochemicals that promote homeostasis, helping to increase resistance to stress, mitigate inflammation, support the skin barrier, and prevent premature aging. A serum containing plant adaptogens demonstrated significant improvements from baseline in global skin quality in subjects with mild-to-severe facial photodamage over 12 weeks.

objectiveWe sought to evaluate the safety and efficacy of a serum containing plant adaptogens (MYS) in subjects with mild-to-moderate persistent centrofacial erythema.

methodsA multicenter, open-label trial enrolled male or female subjects 30 to 65 years of age with mild (2) to moderate (3) persistent centrofacial erythema based on a Modified Clinical Erythema grading scale (M-CEA; 0=clear to 4=severe). A subset of subjects enrolled was taking oral or topical medications for rosacea (≥6 months) with breakthrough erythema. Subjects with >5 papules or pustules were excluded from participation. The investigators assessed erythema based on the M-CEA scale and global inflammatory lesions utilizing a 5-point grading scale (0=none to 4=severe) at baseline, 2, 4, 8, and 12 weeks. Subjects assessed erythema, dryness/flaking, itching, stinging, and burning using a 5-point grading scale (0=none to 4=severe) at baseline, 2, 4, 8, and 12 weeks. Subjects also completed self-assessment questionnaires. Digital photography and adverse events (AEs) were captured throughout the study. In addition to the study product (MYS [AM/PM]), subjects used a standardized skincare regimen that included a gentle cleanser, moisturizer, and sunscreen.

resultsFifty-five subjects were enrolled and 51 subjects completed the study: 38 in the Non-Medication Treatment Group (N-MTG) and 13 in the Medication Treatment Group (MTG). Significant mean reductions in the appearance of erythema of -17%, -25%, -32%, and -33% were demonstrated from baseline at Weeks 2, 4, 8, and 12 (all

conclusionTwice-daily use of a serum comprised of plant adaptogens in subjects with mild-to-moderate persistent centrofacial erythema demonstrated significant reductions in the appearance of erythema from baseline as assessed by investigators and subjects over 12 weeks. Significant reductions from baseline also occurred in papules/pustules. Subjects reported decreases in skin sensitivity and healthier-looking skin.

Indexed as

erythemahomeostasispapules/pustulesPlant adaptogensrosacea

Identifiers

PMID42027414
PMCPMC13102154

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.